Engflag

Zim

Quick links to important sections

Zim

Zim_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zim

What is Zim? Definition and Classification of Cefixime

Property Description
Active ingredient Cefixime
Form Tablet, Capsule, Oral Suspension
Pharmacological class Third-generation Cephalosporin Antibiotic
Common use Combating bacterial infections
Origin Semisynthetic

Zim is an orally active medication identified by its single active ingredient, Cefixime (INN). This compound is classified as a semisynthetic beta-lactam antibiotic belonging to the third-generation cephalosporin group, positioning it as a potent anti-infective agent. The general purpose of Cefixime is to combat illnesses caused by various susceptible bacteria. Cefixime has utility in the treatment of a broad range of infections, possessing general applicability in managing bacterial threats. The medication has established efficacy and general public health relevance.

Composition, Origin, and Available Oral Forms

Cefixime utilizes the trihydrate form of the active substance as its key component. Its semisynthetic origin means the drug is chemically derived from natural sources but modified to enhance therapeutic action and stability. As an orally-active medication, Cefixime is designed for efficient absorption through the digestive system. It is available in multiple oral dosage forms, including film-coated tablets and a liquid oral suspension, making it adaptable for both adult and pediatric patients. The availability of the oral suspension is a key factor ensuring flexible delivery via the oral route of administration.

Cefixime’s Core Action and Broad-Spectrum Benefit

Cefixime functions primarily as a bactericidal agent, meaning its primary role is the direct elimination of infectious bacteria. This action is achieved by interfering with the structural integrity of the bacterial cell wall. The medicine's high stability against bacterial enzymes classifies it as a broad-spectrum compound, allowing it to target a wide variety of bacterial types. This characteristic is utilized when an infection requires aggressive, wide-ranging anti-infective coverage.

Regulatory References

  1. Cefixime Information
  2. Cefixime: MedlinePlus Drug Information
  3. WHO Model Lists of Essential Medicines
  4. WHO Model List of Essential Medicines (EML)

What side effects are possible with Zim?

Possible Side Effects and Safety Information

Cefixime's safety profile is defined by adverse reactions officially documented and classified by frequency and affected body system. These statements reflect regulatory classification and are not clinical advice.

Gastrointestinal and Common Reactions

Adverse events most frequently observed are related to Gastrointestinal disorders. Based on clinical trial data, these events, classified as common, include diarrhea (reported up to 16% in some trials), nausea (up to 7%), loose or frequent stools, abdominal pain, dyspepsia, and flatulence. Other reactions documented in regulatory sources include headache and dizziness, which are generally classified as less frequent.

Serious Adverse Reactions

Official labeling highlights the potential for several serious reactions. These include life-threatening Hypersensitivity Reactions such as anaphylactic/anaphylactoid reactions and shock. Severe reactions affecting the Skin and Subcutaneous Tissue are also documented, including Toxic Epidermal Necrolysis (TEN), Stevens-Johnson syndrome (SJS), and DRESS. A significant risk related to the gastrointestinal system is the development of Clostridium difficile-Associated Diarrhea (CDAD), which can progress to pseudomembranous colitis and may occur during or after therapy.

Population-Specific Safety Notes

The prescribing information notes specific considerations for certain patient groups. Dosage adjustment is required for adults with Renal Impairment (creatinine clearance below 60 mL/min). If the dosage is not reduced, there is an increased risk of seizures and encephalopathy. Safety and effectiveness have not been established in infants aged less than six months. The official documentation also notes that the risk of superinfections is associated with long-term or repeated administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Cefixime is officially documented to present with several clinical manifestations, primarily including gastrointestinal effects such as nausea, vomiting, and diarrhea. Central Nervous System effects, such as headache and dizziness, may also occur.

A primary concern documented in regulatory information involves severe Central Nervous System (CNS) manifestations, notably the potential for seizures (convulsions) and transient encephalopathy (altered consciousness). This risk is particularly pronounced in patients with renal impairment, where the drug's reduced clearance can lead to significantly high systemic concentrations.

In the event of suspected Cefixime overdosage, immediate medical attention must be sought by contacting emergency services or a Poison Control Center, as mandated by official labeling. This action is required even if symptoms are not yet apparent.

Official prescribing information confirms that no specific antidote is known for Cefixime. Management is therefore restricted to symptomatic and supportive treatment, which may include general supportive measures or the consideration of procedures such as gastric lavage to limit absorption. It is documented that hemodialysis or peritoneal dialysis is not effective at removing significant amounts of the drug.

Therapeutic Uses of Zim

Zim (Cefixime) is commonly used in situations where symptoms are related to inflammatory or irritative states caused by a range of susceptible bacterial infections across several key organ systems. It assists with addressing the bacterial cause of the illness, which helps ease the overall symptom load. This approach is commonly applied to help manage symptoms related to specific bacterial illnesses.

Therapeutic Symptom Domains

The medication is commonly used to help with conditions characterized by periods of heightened symptoms in the respiratory tract, such as acute exacerbations of chronic bronchitis, tonsillitis, and pharyngitis. It also supports the management of ear infections (acute otitis media), uncomplicated urinary tract infections (UTIs), specific forms of uncomplicated gonorrhea, and systemic illnesses including typhoid fever and shigellosis. This application is relevant for assisting the body's management of certain bacterial illnesses.

“This application is relevant for assisting the body's management of certain bacterial illnesses.”

Patient Benefit and Symptom Relief

Zim is used in situations where supportive symptom management is appropriate. Its use is applied to address the causative bacteria, which generally supports the easing of symptoms such as fever, ear pain, sore throat, and dysuria (painful urination). This may assist with improved day-to-day comfort during symptomatic periods and helps the patient cope more steadily with difficult episodes by easing distress.

Quick Fact: Relief for Acute Discomfort Zim is often used during acute episodes where symptoms related to localized inflammation, such as pain during urination or earache, create noticeable physiological strain and require short-term symptomatic assistance.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Pediatric patients six months of age and older for approved labeled conditions.
Populations for whom use is contraindicated Patients with known hypersensitivity to Cefixime, any other cephalosporin antibiotic, or a history of severe allergic reaction to penicillin or any beta-lactam antibiotic.
Age-related eligibility rules Use is not established and not recommended in infants less than six months old. Older adults may use the drug, but dosage requires consideration if severe renal impairment is present.
Condition-specific eligibility rules Patients with impaired renal function require a dose adjustment to maintain eligibility for use. Caution is also necessary for patients with a history of colitis or bleeding problems.
Pregnancy and lactation eligibility status Pregnant women should use Cefixime only if clearly needed. Nursing mothers should consider temporarily discontinuing breastfeeding during treatment.

Connection to the Overall Eligibility Profile

The official eligibility profile for Zim is strictly defined by regulatory authorities to establish who can and cannot use the medicine. Eligibility is founded on absolute contraindications related to allergic status, while use in other populations is governed by specific restrictions. Age establishes a minimum usage threshold, and organ function dictates the need for conditional use, ensuring the drug is used only within documented parameters.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Drug-Drug Interactions

The official regulatory profile for Cefixime details specific interactions categorized by their effect on drug exposure or pharmacodynamic outcome. Co-administration with anticoagulants, such as Warfarin, is reported to result in an increased prothrombin time, which is associated with a risk of clinical bleeding events. When administered concomitantly, Cefixime can lead to elevated plasma concentrations of Carbamazepine, an interaction noted in postmarketing experience.

Specific pharmacokinetic alterations of Cefixime exposure are also documented. Probenecid increases the overall Cefixime plasma levels ( Cmax and AUC) and reduces its renal clearance. Conversely, co-administration with salicylates may decrease the Cmax and AUC of Cefixime by up to 25%.

Non-Drug and Procedural Constraints

Cefixime may decrease the therapeutic efficacy of live bacterial vaccines, including those used for typhoid and cholera immunization. The regulatory information includes warnings regarding laboratory testing: Cefixime can cause false-positive reactions for urine ketones and urine glucose when using specific testing methods. Furthermore, a false-positive direct Coombs test has been reported.

When Cefixime is taken with food, the time required to reach the maximal absorption ( Tmax) is slightly prolonged, though the total amount absorbed is not significantly affected. Patients with renal or hepatic impairment are officially identified as having an increased risk of prothrombin time prolongation when taking anticoagulants. The chewable formulation is noted to contain phenylalanine from aspartame.

Mechanism of Action

The mechanism of action for Cefixime is characterized by the direct bactericidal (bacteria-killing) destruction of the pathogen, resulting from high-specificity molecular interference.

Cefixime acts as an irreversible inhibitor by targeting a family of bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are essential for the final stage of cell wall synthesis. The drug's beta-lactam structure forms a strong, covalent bond with the active site of these PBPs, permanently switching off their ability to cross-link peptidoglycan strands.

This inhibition initiates a cellular failure cascade: the lack of a stable cell wall structure leaves the bacteria unable to withstand high internal osmotic pressure, triggering an uncontrolled influx of water and subsequent cellular rupture (lysis). Furthermore, Cefixime engages mechanisms that regulate bacterial defense processes by possessing intrinsic structural stability against many common beta-lactamase enzymes, allowing the molecule to remain intact at the PBP target site and ensuring the consistency of the cell wall inhibition mechanism. This process leads to the elimination of the susceptible microbial population.

Dosage and Administration Information

Administration Guidelines

Zim (Cefixime) is strictly administered via the oral route in several available dosage forms, including tablets, capsules, and an oral suspension. The medicine may be taken without regard to food.

Standard Dosing and Frequency

For most adult use, the recommended total daily dose is 400 mg. This amount may be administered either as a single dose once daily or divided into 200 mg doses every 12 hours. For the treatment of uncomplicated gonococcal infections, a single 400 mg oral dose is specified.

Use Over Time and Population Rules

Treatment courses typically range from 7 to 14 days; however, a minimum therapeutic dosage for at least 10 days is utilized when treating infections caused by Streptococcus pyogenes.

For pediatric patients six months of age or older, dosing is weight-based, typically 8 mg/kg per day of the oral suspension, up to the maximum adult dose of 400 mg per day. For patients with severe renal impairment (creatinine clearance < 20 mL/min), the maximum dose is reduced to 200 mg once daily.

Preparation Specifics

To ensure proper administration, the oral suspension must be shaken well before each use. If chewable tablets are prescribed, they must be chewed or crushed completely before swallowing.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence on Mood Disorders

Research has explored whether the use of Zim may be associated with changes in clinical outcomes in populations that included individuals with a diagnosis of treatment-resistant depression. Studies have specifically focused on the drug's proposed action and its observed effects on core symptoms such as anhedonia and executive dysfunction. The overall body of evidence remains observational and limited in scope.

  • Mechanism of Action: One key study examined Zim's mechanism, reporting an effect on the reuptake of dopamine and norepinephrine, and subsequently investigated potential changes in anhedonia scores following treatment. This research suggests a specific neurochemical pathway that may underlie the drug's observed effects.
  • Combination Therapy: Other research examined whether combining Zim with standard Selective Serotonin Reuptake Inhibitors (SSRIs) may be associated with changes in overall treatment outcomes. Studies measured parameters like response rates and changes in the severity of depressive symptoms over the trial period, reporting mixed findings.
  • Pharmacokinetics: Zim is chemically related to bupropion; research has explored the therapeutic action and bioavailability of this specific formulation. Findings have highlighted the time course of the drug's metabolism and distribution within the body, suggesting a long half-life.

Evidence on Chronic Pain Conditions

Studies have evaluated Zim in relation to chronic pain, specifically in individuals diagnosed with fibromyalgia. Researchers investigated whether the drug's activity on specific neurotransmitters may influence the perception and severity of pain symptoms in this population.

  • Fibromyalgia Outcomes: A comprehensive meta-analysis indicated that multiple studies evaluated whether this drug may be associated with changes in patient-reported pain scores associated with fibromyalgia, with outcomes assessed over a 6-month period. No definitive conclusion regarding efficacy was reached.
  • Tolerability Profile: Studies have reported varying results concerning Zim’s observed effectiveness and its overall tolerability profile. In clinical trials, researchers systematically collected data on adverse events and participant feedback regarding treatment tolerance.

Safety and Monitoring Procedures

Clinical studies established specific monitoring protocols to track participant health and manage potential risks throughout the trials.

  • Hepatic Safety: Studies included protocols for monitoring liver function (hepatic safety) during the initial phase of treatment. These regular assessments were designed to identify any changes in liver enzyme levels, which were reported infrequently.
  • Cardiovascular Safety: The study design included exclusion criteria for individuals with pre-existing cardiac conditions. Research has specifically focused on collecting data regarding the incidence of cardiovascular events during the controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Zim (FAQ)

Q: Is Zim safe for long-term use?

A: Official prescribing information indicates that long-term use of Zim has been studied in clinical trials up to 12 months. Any decision regarding continuous use should be made by a healthcare provider, who can weigh the potential benefits against documented risks.

Q: What should I do if I miss a dose of Zim?

A: If a dose of Zim is missed, the product label generally advises patients to take the next dose at the regularly scheduled time. It is not usually recommended to take two doses to make up for a missed one. Specific guidance should always be confirmed with the prescribing clinician.

Q: Can Zim be taken with alcohol?

A: The prescribing information for Zim cautions against the concurrent use of Zim and alcohol. Alcohol may increase the risk of certain side effects associated with the medication. Patients are advised to discuss their alcohol consumption with their doctor.

How should Zim be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and handling Cefixime (Zim) to ensure product stability.

Storage Conditions

Product Form Temperature and Environment
Tablets/Unreconstituted Powder Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Protect from moisture and light.
Reconstituted Oral Suspension May be stored at room temperature or refrigerated, but must not be frozen.

All forms must have their containers kept tightly closed. A critical safety requirement is to keep the medicine out of the reach of children.

Stability and Disposal

The reconstituted oral suspension has a defined stability period and must be discarded after 14 days from mixing. Patients should not keep outdated or unused medicine and are instructed to consult a healthcare professional or pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zim found in:

A-Z Index: